Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Imiquimod (Primary) ; Fluorouracil
- Indications Squamous cell cancer
- Focus Adverse reactions
- 16 Aug 2018 Planned End Date changed from 28 Sep 2019 to 14 Oct 2019.
- 03 Aug 2018 Planned primary completion date changed from 27 Jul 2019 to 19 Aug 2019.
- 03 Aug 2018 Status changed from not yet recruiting to recruiting.